MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer’s Disease from Public Data

Background Alzheimer's disease (AD) is the most common cause of dementia with no curative therapy currently available. Establishment of sensitive and non-invasive biomarkers that promote an early diagnosis of AD is crucial for the effective administration of disease-modifying drugs. MicroRNAs (miRNAs) mediate posttranscriptional repression of numerous target genes. Aberrant regulation of miRNA expression is implicated in AD pathogenesis, and circulating miRNAs serve as potential biomarkers for AD. However, data analysis of numerous AD-specific miRNAs derived from small RNA-sequencing (RNA-Seq) is most often laborious. Methods To identify circulating miRNA biomarkers for AD, we reanalyzed a publicly available small RNA-Seq dataset, composed of blood samples derived from 48 AD patients and 22 normal control (NC) subjects, by a simple web-based miRNA data analysis pipeline that combines omiRas and DIANA miRPath. Results By using omiRas, we identified 27 miRNAs expressed differentially between both groups, including upregulation in AD of miR-26b-3p, miR-28–3p, miR-30c-5p, miR-30d-5p, miR-148b-5p, miR-151a-3p, miR-186–5p, miR-425–5p, miR-550a-5p, miR-1468, miR-4781–3p, miR-5001–3p, and miR-6513–3p and downregulation in AD of let-7a-5p, let-7e-5p, let-7f-5p, let-7g-5p, miR-15a-5p, miR-17–3p, miR-29b-3p, miR-98–5p, miR-144–5p, miR-148a-3p, miR-502–3p, miR-660–5p, miR-1294, and miR-3200–3p. DIANA miRPath indicated that miRNA-regulated pathways potentially down– regulated in AD are linked with neuronal synaptic functions, while those upregulated in AD are implicated in cell survival and cellular communication. Conclusions The simple web-based miRNA data analysis pipeline helps us to effortlessly identify candidates for miRNA biomarkers and pathways of AD from the complex small RNA–Seq data.

[1]  Daniela Galimberti,et al.  Disease-modifying treatments for Alzheimer’s disease , 2011, Therapeutic advances in neurological disorders.

[2]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[3]  K. Kosik,et al.  MicroRNAs Potentiate Neural Development , 2009, Neuron.

[4]  D. Geldmacher,et al.  Differential diagnosis of Alzheimer's disease , 1997, Neurology.

[5]  A. Delacourte,et al.  Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression , 2008, Proceedings of the National Academy of Sciences.

[6]  Anna M. Krichevsky,et al.  MiR-26b, Upregulated in Alzheimer's Disease, Activates Cell Cycle Entry, Tau-Phosphorylation, and Apoptosis in Postmitotic Neurons , 2013, The Journal of Neuroscience.

[7]  Zoltan Dezso,et al.  Circulating miRNA Biomarkers for Alzheimer's Disease , 2013, Alzheimer's & Dementia.

[8]  Fatih Ozsolak,et al.  RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.

[9]  D. Rueckert,et al.  The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease , 2013, Interface Focus.

[10]  G. Jicha,et al.  Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease , 2012, Experimental Neurology.

[11]  Christina Backes,et al.  Toward the blood-borne miRNome of human diseases , 2011, Nature Methods.

[12]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[13]  Jun-ichi Satoh,et al.  Molecular network analysis of human microRNA targetome: from cancers to Alzheimer’s disease , 2012, BioData Mining.

[14]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[15]  L. Tan,et al.  Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[16]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[17]  E. Wang,et al.  Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma , 2014, Front. Mol. Neurosci..

[18]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[19]  Sabine C. Mueller,et al.  A blood based 12-miRNA signature of Alzheimer disease patients , 2013, Genome Biology.

[20]  W. Huber,et al.  Differential expression analysis for sequence count data , 2010 .

[21]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  Lesley Cheng,et al.  The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies , 2013, Front. Genet..

[23]  A. Antonini,et al.  Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy , 2014, Front. Cell. Neurosci..

[24]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[25]  J. Satoh Molecular network of microRNA targets in Alzheimer's disease brains , 2012, Experimental Neurology.

[26]  H. Juan,et al.  Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. , 2013, Journal of proteome research.

[27]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[28]  C. Rowe,et al.  Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment , 2014, Molecular Psychiatry.

[29]  Sören Müller,et al.  omiRas: a Web server for differential expression analysis of miRNAs derived from small RNA-Seq data , 2013, Bioinform..

[30]  Martin Reczko,et al.  DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways , 2012, Nucleic Acids Res..

[31]  Aikaterini S. Papadopoulou,et al.  Alteration of the microRNA network during the progression of Alzheimer's disease , 2013, EMBO molecular medicine.

[32]  F. Crawford,et al.  Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker Validation Study , 2013, Aging.

[33]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[34]  Sören Müller In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington’s disease , 2014, Translational Neurodegeneration.